Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LATANOPROST

All products: Limited Use (codes 171, 172, 387)

Other products in the same Health Canada class (S01E, S01EE) — coverage varies; not interchangeable

  • Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
  • Latanoprostene bunod (Vyzulta): limited Use 171, 172, 387
  • Travoprost (Izba): limited Use 171, 172, 387
  • Acetazolamide (Acetazolamide): general benefit, Not a benefit
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

11 more in the class list below

Xalatan · DIN 02231493 · 0.005% · Oph Sol-2.5mL Pk

Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Xalatan (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Xalatan · DIN 02231493 Manufacturer: Upjohn Canada ULC; listing date 2000-01-17 Health Canada: Marketed since 2023-07-31 · brand XALATAN · ATC S01EE01 LATANOPROST · form Solution · route Ophthalmic · ingredients LATANOPROST 50 MCG/ML · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $9.5830 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50823 · Verify on the e-Formulary ↗ (DIN 02231493)

Source record
DIN 02231493: Xalatan Raw flags: sec12=Y, sec3=Y Item: 523600088; group id 629; item number 1598; lccId 00089; manufacturer id UJC Source form: Oph Sol-2.5mL Pk; strength: 0.005% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $36.2736; ministry $9.5830 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231493 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50823
Interchangeable products
Apo-Latanoprost · DIN 02296527 · $9.5830 Co Latanoprost · DIN 02254786 · $9.5830 Gd-Latanoprost · DIN 02373041 · $9.5830 Jamp Latanoprost · DIN 02453355 · $9.5830 M-Latanoprost · DIN 02513285 · $9.5830 Med-Latanoprost · DIN 02426935 · $9.5830 Riva-Latanoprost · DIN 02341085 · $9.5830 Sandoz Latanoprost · DIN 02367335 · $9.5830
Shortage status: resolved shortage (ended 2023-03-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231493
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

LATANOPROSTENE BUNOD

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 0.024%w/v · Oph Sol

TRAVOPROST

· 4 products · Limited Use, codes 171, 172, 387 · strengths: 0.003%, 0.004% · Oph Sol (with Preservative), Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: open-angle glaucoma or ocular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BRIMONIDINE TARTRATE & TIMOLOL MALEATE · Limited Use, codes 310, 393 1 INDICATIONS APO-BRIMONIDINE-TIMOP (brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate)) ophthalmic solution is indicated for: • the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution is considered appropriate. PM: https://pdf.hres.ca/dpd_pm/00070296.PDF; date December 14, 2022; DIN 02375311; fetched 2026-09-10 Product monograph LATANOPROSTENE BUNOD · Limited Use, codes 171, 172, 387 1 INDICATIONS VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00048990.PDF; date December 27, 2018; DIN 02484218; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS XALATAN (latanoprost) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. XALATAN may be used for the reduction of intraocular pressure in patients with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty. 1.3 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.4 Geriatrics Geriatrics: Based on the data submitted and reviewed by Health Canada, there is no overall difference in the safety and efficacy of XALATAN use in the geriatric patient population. https://pdf.hres.ca/dpd_pm/00077198.PDF PM date: SEP 25, 2024 Source product: XALATAN; DIN 02231493; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.